Work

AdvanTIG-302 : anti-corps monoclonal anti-TIGIT ociperlimab + tislelizumab dans le cancer du poumon non à petites cellules

Year: 2024

Type: article

Study design: Study Protocol

Source: Revue des Maladies Respiratoires Actualités

DOI: 10.1016/j.rmra.2023.11.552

Authors: X. Quantin, M. Socinski, A. Spira, L. Paz-Ares, M. Reck, S. Lu, T. Sheng, S. Chica-Duque, X. Yu

Institutions: Inserm, Institut de Recherche en Cancérologie de Montpellier, AdventHealth Orlando, The US Oncology Network, Hospital Universitario 12 De Octubre, LungenClinic Grosshansdorf, Zhejiang Cancer Hospital, University of Chinese Academy of Sciences

Language: French

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4390672336

FWCI:

Cites:

Cited by:

Related to: 10